Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADOT - BIOMODA: Profitable Technology with Purpose -- Ignore unavailable to you. Want to Upgrade?

To: Brad who wrote (1450)	8/12/1998 11:08:00 AM
From: erin4	Read Replies (1) \| Respond to of 4650

AOL quote has ADOT down 15 cents today. I think someone misplaced the decimal point.

To: Brad who wrote (1450)	8/12/1998 11:47:00 AM
From: walleye	Read Replies (1) \| Respond to of 4650

Brad, I e-mailed the folks at Lungcheck (the company testing Biomoda's cancer detection system) to see if they could give me information on biomoda's testing. Their response follows: Dear Walleye: At this point, our work with BioModa is just getting off the ground. As is normal in joint studies of this nature, both parties have agreed not to reveal any results of our analysis until the study is complete. We expect that the initial phase of the study will be done by September as noted in the release. At that time, BioModa will make the decision as to what is announced. I will make one observation on the issue of early detection. As is true with virtually all forms of cancer, the earlier the cancer is found, the greater the chance of a successful treatment program. LungCheck currently offers a comprehensive service that analyzes the fluids in the lungs (called sputum) for evidence of cancerous and pre-cancerous cells. In addition, we quantify the incidence of other cells in the lungs that are an indication of the degree of lung inflammation. It is our belief that our type of analysis can lead to an earlier diagnosis than a lung xray, which is a common form of diagnosis today. Several studies have shown that by the time a lung cancer lesion is visible on an xray, the five year survival rate is under 15%. We are trying to improve that statistic. Our work with BioModa and others is motivated by the desire to continually improve our test. I have passed your email on to BioModa in the event that they wish to respond in more detail to your other questions. Sincerely yours John E. Ledermann Vice President LungCheck Inc. I hope this helps, BE HAPPY, WALLEYE